Hoosier entrepreneurs in health care and life sciences attracted more than $31 million from investors during the first half of the year. But too few Indiana companies have developed their technology enough to attract venture capitalists or tap stock markets.
Strand Diagnostics lost a key court battle on July 30 when a federal judge in Indianapolis granted summary judgment in favor of the Medicare program, which has refused to reimburse Strand for its test since 2012.
With this year’s bill estimated at $37 billion and counting, perhaps the sheer cost of cleaning up after IT security breaches at health care organizations will spur the industry to find a bandage for its hemorrhaging computer systems.
Hospitals around Indiana have added 2,400 jobs since September as profits, patient visits and insurance coverage all improved.
Anthem turned out unheard of gains in 2014, the first year of Obamacare’s new health insurance overhaul, as Anthem’s customers numbers held steady but their spending with hospitals and doctors plummeted.
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
The plan by the Medicare program to require hospitals in Indianapolis and 74 other cities to accept one payment for joint replacement surgeries is a huge step in fixing the crazy prices and spending growth in health care.
The large practice of orthopedic surgeons is in the midst of spending $3.8 million over three years to open seven urgent care clinics specializing in orthopedic-related injuries.
With Anthem and IU Health so hot to trot their anti-smoking bona fides, it’s surprising their responses to The New York Times' stories about the U.S. Chamber of Commerce blocking anti-smoking policies overseas have been so tepid.
The money, known as reinsurance payments, helped MDwise, Anthem, Humana, Assurant and the Physicians Health Plan of Northern Indiana keep a lid on their losses even as lots of new patients with expensive or untreated medical conditions migrated into the private insurance market.
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Michael A. Byers’ Tooth Bank is one of a tiny group of U.S. companies catering to the latest iteration of stem cell therapy: harvesting stem cells from the pulp inside baby teeth and extracted wisdom teeth, then culturing, freezing and storing them at a cryostorage facility for later use.
Last week’s Supreme Court ruling upholding the tax credits for Obamacare is just the latest in a string of developments that have kept employers from ditching their group health plans, as many predicted they would.
For at least 20 years, Republicans have been pushing for giving tax credits to help individuals buy health insurance. The Supreme Court’s latest Obamacare ruling does Republicans the favor of preserving them.
London Mayor Boris Johnson is proposing a $16 billion fund to encourage growth of emerging health-care companies in the United Kingdom in an effort to catch up to biotechnology clusters in the United States.
The Indiana-based company has taken the name Zimmer Biomet Holdings Inc. and will trade under the ticker symbol to "ZBH" on Monday. Zimmer Holdings Inc. agreed to buy privately-held Biomet in April 2014.
